113 related articles for article (PubMed ID: 15736197)
1. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent.
Hammell DC; Stolarczyk EI; Klausner M; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Apr; 94(4):828-36. PubMed ID: 15736197
[TBL] [Abstract][Full Text] [Related]
2. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.
Pillai O; Hamad MO; Crooks PA; Stinchcomb AL
Pharm Res; 2004 Jul; 21(7):1146-52. PubMed ID: 15290853
[TBL] [Abstract][Full Text] [Related]
4. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
5. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin.
Stinchcomb AL; Swaan PW; Ekabo O; Harris KK; Browe J; Hammell DC; Cooperman TA; Pearsall M
J Pharm Sci; 2002 Dec; 91(12):2571-8. PubMed ID: 12434400
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
7. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.
Valiveti S; Paudel KS; Hammell DC; Hamad MO; Chen J; Crooks PA; Stinchcomb AL
Pharm Res; 2005 Jun; 22(6):981-9. PubMed ID: 15948042
[TBL] [Abstract][Full Text] [Related]
8. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
Banks SL; Pinninti RR; Gill HS; Crooks PA; Prausnitz MR; Stinchcomb AL
Pharm Res; 2008 Jul; 25(7):1677-85. PubMed ID: 18449628
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs.
Valiveti S; Hammell DC; Paudel KS; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2005 Feb; 102(2):509-20. PubMed ID: 15653167
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion.
Kiptoo PK; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2006 Jun; 113(2):137-45. PubMed ID: 16750868
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
12. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone.
Vaddi HK; Banks SL; Chen J; Hammell DC; Crooks PA; Stinchcomb AL
J Pharm Sci; 2009 Aug; 98(8):2611-25. PubMed ID: 18972573
[TBL] [Abstract][Full Text] [Related]
13. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug.
Nalluri BN; Milligan C; Chen J; Crooks PA; Stinchcomb AL
Drug Dev Ind Pharm; 2005 Oct; 31(9):871-7. PubMed ID: 16305998
[TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.
Kiptoo PK; Paudel KS; Hammell DC; Hamad MO; Crooks PA; Stinchcomb AL
Eur J Pharm Sci; 2008 Apr; 33(4-5):371-9. PubMed ID: 18321686
[TBL] [Abstract][Full Text] [Related]
15. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.
Milewski M; Yerramreddy TR; Ghosh P; Crooks PA; Stinchcomb AL
J Control Release; 2010 Aug; 146(1):37-44. PubMed ID: 20678989
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.
Eldridge JA; Milewski M; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2014 Nov; 24(22):5212-5. PubMed ID: 25442314
[TBL] [Abstract][Full Text] [Related]
17. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone.
Vaddi HK; Hamad MO; Chen J; Banks SL; Crooks PA; Stinchcomb AL
Pharm Res; 2005 May; 22(5):758-65. PubMed ID: 15906171
[TBL] [Abstract][Full Text] [Related]
18. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
19. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
Milewski M; Stinchcomb AL
Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog].
Li H; Zhao SF; Wang N; Ge ZH
Yao Xue Xue Bao; 1996; 31(4):254-7. PubMed ID: 9208648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
